Abstract: A method of acquiring magnetic resonance imaging (MRI) data from an MRI scan of an object includes generating a number of excitation sequences by, in order: generating an excitation pulse, generating an imaging magnetic field gradient, and generating a spoiler magnetic field gradient. MRI data is acquired during the generation of the spoiler magnetic field gradients. The spoiler magnetic field gradients are selected such that, during each excitation sequence, substantially the same k-space trajectory is traversed during the generation of the spoiler magnetic field gradient.

Abstract: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.

Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: There is provided a method of aggregating a plurality of beads in a magnetic bead aggregation assay for subsequent analysis comprising: —providing magnetic beads comprising a capture probe for binding with said target analyte; —reacting the magnetic beads with the sample including a target analyte in a reaction chamber aggregating the magnetic beads in the presence of a magnetic field with the target analyte to allow formation of magnetic bead aggregates having physical properties detectable to enable characterization of the aggregates on an aggregate by aggregate basis using a detector to measure the physical properties of the aggregates. Further provided are a method and system for detecting analytes in a sample by characterizing the magnetic bead aggregates on an aggregate by aggregate basis by measuring physical properties of the aggregates.

Abstract: The disclosure concerns a prognostic method for determining at least one, or a combination, of the following: time to first treatment, response to treatment or overall survival for a patient presenting with a disease including or characterized by telomere shortening, including an assessment of the longest mean telomere length at which telomere end-end fusion events can be detected and then a determination of the mean telomere length in the fusogenic range (i.e. the range below that mean telomere length at which telomere end-end fusion events can be detected) and the subsequent use of the mean telomere length in the fusogenic range as a prognostic indicator.

Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: Embodiments for testing embedded systems and their applications in an Internet of Things (IoT) environment by a processor, denoted as a Hardware-in-the-Loop as a Service (HiLaaS). In a simulated environment, one or more simulated entities and one or more real entities in a networked system may be tested in real-time according to received control parameters, for a price. The price is estimated by the system, based on other parameters, and offered to the user to accept or reject. Alternatively, the user may specify the price, the system estimates control parameters, and the user can accept or reject the control parameters. One or more properties of the one or more entities, the network system, or combination thereof may be estimated based on the testing of the one or more simulated entities, when the price and control parameters are accepted.

Abstract: There is provided a method, a system and a computer program product for supporting a decision making process. The system receives a decision model from a decision maker, the decision model used for determining a solution to a decision problem based on attributes and uncertainties of the decision problem. The decision problem includes information about a plurality of outcome vectors that represent all possible outcomes and the uncertainties associated with the decision problem. The system determines whether the received decision model can be solved without receiving any preference information from the decision maker. The system receives partially specified preference information from the decision maker if the received decision model cannot be solved without any preference information. The system solves the decision model with the partially specified preference information. The system recommends, based on the solution, one or more decisions to the decision maker.

Abstract: A sleep monitoring system includes an ECG device and a respiration inductance plethysmogram which monitor cardiac activity and physical respiration respectively and feed representative signals to a digital data processor. Operations process the beat interval data, while in a second thread, operations independently process the amplitude modulation of the ECG data caused by the respiratory motion of the subject. The inductance plethysmogram device provides an input to the processor which represents respiration as directly monitored independently of the ECG. Operations process this direct respiration data independently and in parallel, in a third thread. All extracted features are fed to a classifier which in step combines selected combinations of features to make decisions in real time.

Abstract: A novel and useful mm-wave frequency generation system is disclosed that takes advantage of injection locking techniques to generate an output oscillator signal with improved phase noise (PN) performance and power efficiency. Low frequency and high frequency DCOs as well as a pulse generator make up the oscillator system. A fundamental low frequency (e.g., 30 GHz) signal and its sufficiently strong higher (e.g., fifth) harmonic (e.g., 150 GHz) are generated simultaneously in a single oscillator system. The second high frequency DCO having normally poor phase noise is injected locked to the first low frequency DCO having good phase noise. Due to injection locking, the high frequency output signal generated by the second DCO exhibits good phase noise since the phase noise of the second DCO tracks that of the first DCO.

Abstract: A novel and useful discrete time IIR bandpass filter is disclosed that takes advantage of clock phase reuse thereby leading to significant improvements in filtering, especially stop band rejection in comparison to prior art filters. The bandpass filter of the present invention achieves improved filtering performance without adding any additional clock phases to the circuit. In particular, reuse of the already existing clock phases increases the order and performance of the filter. The invention exploits reuse of the clock phases to provide higher order filtering along with a discrete time IIR filter design which is capable of operating at high frequency. Consequently, much better filtering is achieved and the quality factor of the filter is improved leading to sharper transition bands especially for close-in band blockers in modern 4G/5G receivers.

Abstract: The invention relates to a sensor molecule for detecting a target molecule comprising: (a) a rod-like molecule L and a rod-like molecule R connected to each other by a joint molecule C to form a hinge; (b) a target binding molecule A bonded to the end of rod-like molecule L opposite to the joint molecule C; (c) a binding molecule A? bonded to the end of rod-like molecule R opposite the joint molecule C; wherein the target binding molecule A is arranged to bind to an epitope or nucleic acid sequence of the target molecule to be detected, and binding molecule A? is arranged to bind to the same epitope or same nucleic acid sequence, or portion thereof of the target molecule as target binding molecule A; and wherein the hinge is biased into an open position, such that target binding molecule A and binding molecule A? are biased apart by the hinge. The invention also relates to analyte dependent activation of pharmaceuticals and chemo-toxins.

Abstract: The invention relates to novel chemical entities that act as thromboxane (TX) A2 receptor, or T prostanoid receptor (TP), antagonists and to their use in the treatment of human diseases in which thromboxane (TX) A and of all other agents that act as incidental ligands of TP, including the endoperoxide prostaglandin (PG)G2/PGH2, 20-hydroxyeicosatetraenoic acid (20-HETE) and the free-radical derived isoprostanes (e.g., 8-iso-prostaglandin (PG)F2?), play a role. Compounds of the invention preferably include a benzenesulfonyl urea in which the benzene is substituted by a substituted biphenylyloxy group (e.g., at the 2 position) and by a nitrile group (e.g., at the 5 position), which compounds show promising results as TP-isoform selective TP antagonists.

Abstract: A method for performing high dynamic range optical image detection of a scene. The method comprises imaging incident light from a scene onto an object plane of an Optical Array Device, the OAD operating in time modulation mode; determining the locations of those pixels in the object plane of a first light level; detecting the optical irradiance values of those pixels of the first light level to produce a first detected image; detecting the optical irradiance values of those pixels of a second light level to produce a second detected image; and generating a high dynamic range optical irradiance map of the scene by combining the first detected image and the second detected image into a single image.

Abstract: A primary video and a second instance of a reference video can be simultaneously transmitted to a system through at least a first node of a communication network, the second instance of the reference video configured to be compared to a first instance of the reference video stored by the system to generate at least one quality of experience (QoE) value that infers a perceptual quality of the primary video as received by the system. The QoE value can be received from the system. A determination can be made as to whether the QoE value is less than a threshold value. Responsive to determining that the QoE value is less than the threshold value, the perceptual quality of the primary video can be improved by re-routing transmission of the primary video to the system.

Abstract: A novel and useful high-order discrete-time charge rotating (CR) infinite impulse response (IIR) low pass filter is presented. The filter utilizes history capacitor arrays incorporating banks of capacitors. A linear interpolation technique is used in the IIR filter with second order antialiasing filtering, whose transfer function is sinc(x)2 per stage. It also uses a gm cell, rather than operational amplifiers, and is thus compatible with digital nanoscale technology. A 7th-order charge-sampling discrete time filter is disclosed. The order of the filter is easily extendable to higher orders. The charge rotating filter is process scalable with Moore's law and amenable to digital nanoscale CMOS technology. Bandwidth of the filter is precise and robust to PVT variation. The filter exhibits very low power consumption per filter pole, low input-referred noise, wide tuning range, excellent linearity and low area per minimum bandwidth and filter pole.

Abstract: A novel and useful variable step serial DAC having a desired trajectory between input samples with a defined slope at intermediate points to form the output dynamic curve. The serial DAC is implemented to achieve higher order interpolation between the input sample points in the analog domain using switched capacitor CMOS circuits and without the use of a sample and hold circuit at the output. Conceptually, only two capacitors are needed for defining the output voltage for the conventional serial DAC. Dynamically programmable capacitor arrays define, via digital codes, the desired interpolation trajectory or output curve for the DAC between input sample points by defining the ratio of input charge Q(i) to the total capacitance C(i) at the ith time interval [Q(i)/C(i)]. The voltage at the output of the DAC is defined by incremental charge transfer at a defined rate between the input sample points. This technique uses minimum energy and area to define the dynamic curve for the DAC.

Abstract: An on-diaper body fluid screening device (100), comprising a stack of the following sheets: a surface sheet (110) permeable to body fluid, a collection sheet (120) impervious to body fluid, a testing sheet (130), which is body fluid absorbent and provided with colorimetric assay reaction pads (131), and which is provided with a body fluid barrier network (132) forming body fluid channels (134) between an inlet section (135) and the colorimetric assay reaction pads (131), a protection sheet (140) impervious to body fluid, and a transparent readout sheet (150), through which the assay reaction pads (131) are visible. The protection sheet (140) comprises pad receiving openings (142). The collection sheet (120) comprises an inlet hole (125) which is arranged over the inlet section (135). A swelling component (702) is arranged in association with the inlet hole (125) and an inlet hole closing member (601).

Abstract: Provided herein are methods for treating an individual having (suffering from) an acute myocardial infarction and drug eluting stents useful for treating such individuals. These methods include treating an individual by introducing, such as by surgically inserting, at a site of an acute coronary artery occlusion upstream of the site of acute myocardial infarction, a drug eluting stent (DES) that is capable of eluting from 25 pg to 950 pg of IGF-1 directly into the coronary circulation. The treatment is specifically directed to stimulation of repair or survival of damaged cardiac muscle or left ventricular remodeling.

Abstract: The present application relates to compounds of any one of Formulae I, Ia, Ib, Ic, Id, Ie, and If. Compounds of Formula (I) have the structure: wherein A, B, W, Y, Z, R2, R4, R5, R6, Rq and q are as defined herein. The compounds can be used as inhibitors of Bcl-3 and can be used for the treatment of cancer, particularly metastatic cancer.